|Description||BMS-279700, belonging to a family of novel anilino 5-azaimidazoquinoxaline analogues, is an orally active lead candidate that blocks the production of proinflammatory cytokines (IL-2 and TNFalpha) in vivo.|
|Synonyms||(S)-N-(2-chloro-6-methylphenyl)-2-(3-methylpiperazin-1-yl)imidazo[1,5-a]pyrido[3,2-e]pyrazin-6-amine; BMS279700; BMS 279700; BMS-279700|
Pentagalloylglucose, a polyphenol isolated from the fruits of Pistacia lentiscus, increases a population of Treg cells in conjunction with Treg-inducing factors...
IL5 receptor antagonist
Secukinumab is a recombinant human IgG1κ monoclonal antibody that specifically binds to and inhibits interleukin (IL)-17A. Secukinumab was developed by Novartis...
Apilimod is a potent and orally bioavailable inhibitor of the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23) with the potential to treat certain au...
SU 5201 is an inhibitor of IL-2 production.
Y-320 is a new phenylpyrazoleanilide immunomodulator that inhibits IL-17 production by CD4 T cells stimulated with IL-15 with IC50 values of 20 to 60 nM.
Ladarixin is Interleukin 8A and Interleukin 8B receptor antagonist. IL-8A and IL-8B inhibition blocks and reverses type 1 diabetes in mice. In Dec 2015, Phase-I...
Tyrphostin A1, can be as a negative control for inhibition of EGFR (IC50 >1250 µM) and was shown to inhibit the tyrosine phosphorylation of IL-2 stimulated Tyk-...